Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease

US11649227B2 · kind B2 · utility

Assignee

• PETRA PHARMA CORPORATION · US

Inventors

• Erin Danielle ANDERSON · Boulder, US
• Sean Aronow · Boulder, US
• Nicholas Boyles · Hillsboro, US
• Markus Dahlgren · Stratford, US
• Shulu FENG · Ridgewood, US
• Aleksey I. Gerasyuto · Flemington, US
• Eugene Richard Hickey · Danbury, US
• Thomas Combs IRVIN · Erie, US
• Edward A. Kesicki · Bothell, US
• Anke Klippel-Giese · Berchtesgaden, DE
• Jennifer Lynn KNIGHT · Jersey City, US
• Gabrielle R. Kolakowski · Boulder, US
• Manoj KUMAR · Longmont, US
• Katelyn Frances LONG · Lafayette, US
• Christopher Mayne · Boulder, US
• David L. McElligott · Bothell, US
• Johnathan Alexander McLean · Indianapolis, US
• Loredana PUCA · New York, US
• Kannan Karukurichi RAVI · Fords, US
• Daniel Lee Severance · San Diego, US
• Michael Brian WELCH · Westminster, US
• Tien WIDJAJA · Lafayette, US

Key dates

• Filing date: Apr 2, 2021
• Grant date: May 16, 2023
• Expiry date: Apr 2, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/056
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.